Treatment of venous thromboembolism: Challenging the unfractionated heparin standard

Pharmacotherapy

Volumn 24, Issue 8 II, 2004, Pages

  Nutescu, Edith ^a   Singh Khalsa, Manider ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Cigna   (United States)

Author keywords

Activated partial thromboplastin time; Low molecular weight heparins; Nomograms; Unfractionated heparin; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; COUMARIN ANTICOAGULANT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; META ANALYSIS; MORTALITY; OUTPATIENT CARE; PARTIAL THROMBOPLASTIN TIME; RECURRENT DISEASE; THROMBOEMBOLISM; TREATMENT OUTCOME;

CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, INTRAVENOUS; VENOUS THROMBOSIS;

EID: 3543093189     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.12.127S.36112     Document Type: Conference Paper

References (41)

1. De Wet CJ, Pearl RG. Postoperative thrombotic complications: venous thromboembolism: deep-vein thrombosis and pulmonary embolism. Anesthesiot Clin North Am 1999;17: 895-922.
2. Kniffin WD, Baron JA, Barret J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly Arch Intern Med 1994;154:861-6.
3. Giuntini C, Di Ricco G, Marini C, et al. Pulmonary embolism: epidemiology, pathophysiology, diagnosis, and management. Chest 1995;107(suppl 1):3-9.
4. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-93.
5. Wheeler HB. Diagnosis of deep vein thrombosis: review of clinical evaluation and impedance plethysmography Am J Surg 1985;150:7-13.
6. Landefeld CS, McGuire E, Cohen AM. Clinical findings associated with acute proximal deep vein thrombosis: a basis for quantifying clinical judgment. Am J Med 1990;88:382-8.
7. Deitelzweig SB, Vanscoy GJ, Niccolai CS, Rihn TL. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients. Ann Pharmacother 2003;37: 402-11.
8. Enders JM, Burke JM, Dobesh PP. Prevention of venous thromboembolism in acute care medical patients. Pharmacotherapy 2002;22:1564-78.
9. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals from the council on thrombosis (in consultation with the council on cardiovascular radiology), American Heart Association. Circulation 1996;93:2212-45.
10. Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003;163:759-68.
11. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960;1: 1309-12.
12. Kernohan RJ, Todd C. Heparin therapy in thromboembolic disease. Lancet 1966;1;621-3.
13. Alpert JS, Smith R, Carlson CJ, et al. Mortality in patients treated for pulmonary embolism. JAMA 1976;236:1477-80.
14. Kanis JA. Heparin in the treatment of pulmonary thromboembolism. Thromb Haemost 1974;32:517-27.
15. Brandjes DPM, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-9.
16. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S-93.
17. Gallus A, Jackaman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986;2:1293-6.
18. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-4.
19. Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:325-7.
20. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986;315:1109-14.
21. Chui HM, Hirsh J, Yung WL, et al. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977;49:171-84.
22. Doyle DJ, Turpie AG, Hirsh J, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis: a randomized trial. Ann Intern Med 1987;107:441-5.
23. Pini M, Pattacini C, Quintavalla R, et al. Subcutaneous vs. intravenous heparin in the treatment of deep venous thrombosis: a randomized clinical trial. Thromb Haemost 1990;64:222-6.
24. Anderson G, Fagrell B, Holmgren K, et al. Subcutaneous administration of heparin: a randomized comparison with intravenous administration of heparin to patients with deep-vein thrombosis. Thromb Res 1982;27:631-9.
25. Fennerty AG, Thomas P, Backhouse G, et al. Audit of control of heparin treatment. BMJ 1985;290:27-8.
26. Reilly B, Raschke R, Sandhya S, et al. Intravenous heparin dosing: patterns and variations in internist's practices. J Gen Intern Med 1993;8:536-42.
27. Hull RD, Raskob GE, Lemaire J, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Int Med 1992;152:1589-95.
28. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a 'standard care' nomogram: a randomized controlled trial. Ann Intern Med 1993;119:874-81.
29. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Int Med 1991;151:333-7.
30. Hull RD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy: the emerging theme of delayed recurrence. Arch Intern Med 1997;157:2317-21.
31. Wilson JE III, Bynum LJ, Parkey RW. Heparin therapy in venous thromboembolism. Am J Med 1981;70:808-16.
32. Hull RD, Raskob GE, Brant RF, et al. Relation between the time to achieve the lower limit of the aPTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997;157:2562-8.
33. Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal vein thrombosis. Lancet 1992;339:441-5.
34. Liebowitz RS. Deep venous thrombosis: thinking inside out. [editorial] Arch Intern Med 1998:158:1964.
35. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
36. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Int Med 2000;160:181-8.
37. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. Ann Intern Med 1999;130:800-9.
38. Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-77.
39. Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis: an updated meta-analysis. Drugs 1996;52(suppl 7):30-7.
40. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 1995;155:601-7.
41. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994;309:299-304.